Surrozen, Inc./DE Deferred Tax Assets, Operating Loss Carryforwards
Surrozen, Inc./DE (SRZN) had Deferred Tax Assets, Operating Loss Carryforwards of $41.05 million as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-23
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $41.05M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $34.05M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $36.40M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $32.98M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $41.05M 10-K · filed 2026-03-23 |
| 2024-12-31 | $34.05M 10-K · filed 2026-03-23 |
| 2023-12-31 | $36.40M 10-K · filed 2025-03-31 |
| 2022-12-31 | $32.98M 10-K · filed 2024-04-10 |
| 2021-12-31 | $31.83M 10-K · filed 2023-03-31 |
| 2020-12-31 | $22.59M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |